These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26421813)

  • 1. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review.
    Clement SC; Peeters RP; Ronckers CM; Links TP; van den Heuvel-Eibrink MM; Nieveen van Dijkum EJ; van Rijn RR; van der Pal HJ; Neggers SJ; Kremer LC; van Eck-Smit BL; van Santen HM
    Cancer Treat Rev; 2015 Dec; 41(10):925-34. PubMed ID: 26421813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin.
    Rosario PW; Calsolari MR
    Thyroid; 2013 May; 23(5):617-9. PubMed ID: 23136908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
    Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors.
    Sawka AM; Lakra DC; Lea J; Alshehri B; Tsang RW; Brierley JD; Straus S; Thabane L; Gafni A; Ezzat S; George SR; Goldstein DP
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):479-90. PubMed ID: 18284643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
    Corrêa NL; de Sá LV; de Mello RC
    Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up.
    Baudin C; Bressand A; Buffet C; Menegaux F; Soret M; Lê AT; Cardon T; Broggio D; Bassinet C; Huet C; Armengol G; Richardson DB; Leenhardt L; Bernier MO; Lussey-Lepoutre C
    Thyroid; 2023 Sep; 33(9):1100-1109. PubMed ID: 37300484
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.
    Auttara-Atthakorn A; Sungmala J; Anothaisintawee T; Reutrakul S; Sriphrapradang C
    Front Endocrinol (Lausanne); 2022; 13():960265. PubMed ID: 36105397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.
    Solans R; Bosch JA; Galofré P; Porta F; Roselló J; Selva-O'Callagan A; Vilardell M
    J Nucl Med; 2001 May; 42(5):738-43. PubMed ID: 11337569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer.
    Albano D; Bertagna F; Panarotto MB; Giubbini R
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
    Bhattacharyya N; Chien W
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
    Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
    J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study.
    Klein Hesselink EN; Brouwers AH; de Jong JR; van der Horst-Schrivers AN; Coppes RP; Lefrandt JD; Jager PL; Vissink A; Links TP
    J Nucl Med; 2016 Nov; 57(11):1685-1691. PubMed ID: 27339871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables.
    Gandhi S; Abhyankar A; Basu S
    Nucl Med Commun; 2014 Feb; 35(2):205-9. PubMed ID: 24217429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioactive iodine: An unappreciated threat to salivary gland function.
    Sunavala-Dossabhoy G
    Oral Dis; 2018 Mar; 24(1-2):198-201. PubMed ID: 29480611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
    Reiners C; Schneider R; Platonova T; Fridman M; Malzahn U; Mäder U; Vrachimis A; Bogdanova T; Krajewska J; Elisei R; Vaisman F; Mihailovic J; Costa G; Drozd V
    Front Endocrinol (Lausanne); 2020; 11():381. PubMed ID: 32754115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salivary gland malignancy and radioiodine therapy for thyroid cancer.
    Klubo-Gwiezdzinska J; Van Nostrand D; Burman KD; Vasko V; Chia S; Deng T; Kulkarni K; Wartofsky L
    Thyroid; 2010 Jun; 20(6):647-51. PubMed ID: 20470209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment.
    Fallahi B; Adabi K; Majidi M; Fard-Esfahani A; Heshmat R; Larijani B; Haghpanah V
    Clin Nucl Med; 2011 Apr; 36(4):277-82. PubMed ID: 21368600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
    Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
    BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.